# Otsuka Pharmaceutical Co., Ltd. clinical trials: 143 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 143 trials with Otsuka Pharmaceutical Co., Ltd. as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Otsuka Pharmaceutical Co., Ltd.: 143 rows for $7.15, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/otsuka-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 143
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 25 newest of 143, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2025 | NCT07225712 | A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Schizophrenia | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225712) |
| September 22, 2025 | NCT07184645 | A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Atopic Dermatitis (AD) | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07184645) |
| September 15, 2025 | NCT07173478 | A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Atopic Dermatitis (AD) | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07173478) |
| July 28, 2025 | NCT07087327 | A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Attention-Deficit Hyperactivity Disorder(ADHD) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07087327) |
| July 25, 2025 | NCT07086313 | A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | Otsuka Pharmaceutical Co., Ltd. | Phase 2/3 | Recruiting | Attention-Deficit Hyperactivity Disorder(ADHD) | 315 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07086313) |
| July 8, 2025 | NCT07053891 | LUPKYNIS Drug-use Results Survey | Otsuka Pharmaceutical Co., Ltd. | Observational | Recruiting | Lupus Nephritis | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053891) |
| April 16, 2025 | NCT06931080 | Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients | Otsuka Pharmaceutical Co., Ltd. | Phase 2/3 | Recruiting | Attention Deficit Hyperactivity Disorder (ADHD) | 630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06931080) |
| April 15, 2025 | NCT06926829 | A Long-term Trial of EB-1020 in Adult Patients With ADHD | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Attention Deficit Hyperactivity Disorder (ADHD) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926829) |
| March 14, 2025 | NCT06875986 | REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia | Otsuka Pharmaceutical Co., Ltd. | Observational | Recruiting | Alzheimer Disease | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06875986) |
| September 13, 2023 | NCT06036108 | Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia | Otsuka Pharmaceutical Co., Ltd. | Phase 1 | Completed | Schizophrenia | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06036108) |
| February 3, 2023 | NCT05712746 | Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure. | Otsuka Pharmaceutical Co., Ltd. | Observational | Active not recruiting | Heart Failure | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05712746) |
| January 17, 2023 | NCT05687071 | A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Completed | Hyper-low-density Lipoprotein (LDL) Cholesterolemia | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05687071) |
| January 13, 2023 | NCT05683340 | A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Completed | Hyper-low-density Lipoprotein (LDL) Cholesterolemia | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05683340) |
| November 14, 2022 | NCT05615363 | A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure \[CHF\]) | Otsuka Pharmaceutical Co., Ltd. | Phase 2 | Completed | Cardiac Edema (CHF) | 157 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05615363) |
| May 13, 2022 | NCT05372653 | A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Completed | Atopic Dermatitis (AD) | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05372653) |
| April 22, 2022 | NCT05342493 | Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use | Otsuka Pharmaceutical Co., Ltd. | Observational | Recruiting | Migraine Disorders | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05342493) |
| April 13, 2022 | NCT05326347 | A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Completed | Schizophrenia | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05326347) |
| April 13, 2022 | NCT05325645 | Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Acute Schizophrenia | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05325645) |
| November 15, 2021 | NCT05119894 | A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia | Otsuka Pharmaceutical Co., Ltd. | Phase 1 | Withdrawn | Schizophrenia | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05119894) |
| March 23, 2021 | NCT04812379 | Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP) | Otsuka Pharmaceutical Co., Ltd. | Observational | Completed | Bipolar Disorder I | 535 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04812379) |
| March 10, 2021 | NCT04790175 | Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH | Otsuka Pharmaceutical Co., Ltd. | Observational | Active not recruiting | Antidiuretic Hormone, Inappropriate Secretion | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04790175) |
| March 5, 2021 | NCT04784442 | A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia | Otsuka Pharmaceutical Co., Ltd. | Phase 2 | Completed | Hypercholesterolemia | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04784442) |
| December 2, 2020 | NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | Otsuka Pharmaceutical Co., Ltd. | Phase 1/2 | Terminated | Multiple Myeloma (MM) | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04649073) |
| April 24, 2020 | NCT04362007 | A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | Otsuka Pharmaceutical Co., Ltd. | Phase 1/2 | Terminated | Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04362007) |
| April 21, 2020 | NCT04355117 | A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients | Otsuka Pharmaceutical Co., Ltd. | Phase 3 | Completed | Migraine | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04355117) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 27 |
| Phase 1/2 | 3 |
| Phase 2 | 33 |
| Phase 2/3 | 12 |
| Phase 3 | 53 |
| Phase 4 | 4 |
| Not applicable | 1 |
| Observational | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 123 |
| Recruiting | 9 |
| Terminated | 5 |
| Active not recruiting | 3 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 11 |
| Dermatitis, Atopic | 9 |
| Heart Failure | 9 |
| Parkinson Disease | 7 |
| Dry Eye Syndromes | 6 |
| Depressive Disorder, Major | 6 |
| Leukemia, Myeloid, Acute | 5 |
| Migraine Disorders | 5 |
| Fibrosis | 4 |
| Ascites | 4 |
| Attention Deficit Disorder with Hyperactivity | 4 |
| Alcoholism | 4 |
| Edema, Cardiac | 4 |
| Kidney Failure, Chronic | 3 |
| Autistic Disorder | 3 |
| Glaucoma | 3 |
| Ocular Hypertension | 3 |
| Polycystic Kidney, Autosomal Dominant | 3 |
| Edema | 2 |
| Cerebral Infarction | 2 |
| Recurrence | 2 |
| Arthritis, Rheumatoid | 2 |
| Crohn Disease | 2 |
| Inappropriate ADH Syndrome | 2 |
| Carcinoma, Hepatocellular | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Beauty product suppliers in the United States](https://specstream.ai/data/businesses/beauty-product-suppliers/united-states)
- [Temp agencies in the United States](https://specstream.ai/data/businesses/temp-agencies/united-states)
- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Gluten free restaurants in the United States](https://specstream.ai/data/businesses/gluten-free-restaurants/united-states)
- [Chemical plants in the United States](https://specstream.ai/data/businesses/chemical-plants/united-states)
